You are here: Industry Insights > FibroGenesis

News List

FibroGenesis Reports Positive Data in Pancreatic, Breast Cancer Using Fibroblast-Based Immunotherapy americanpharmaceuticalreview
February 20, 2021
FibroGenesis announced new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer.
FibroGenesis Announces the Filing of its 250th Patent for Fibroblast Cell Therapy Platform prnasia
November 13, 2020
FibroGenesis, a Texas-based regenerative medicine company focused on tissue regeneration and chronic disease reversal using Human Dermal Fibroblasts (HDFs), announced the filing of its 250th patent related to its fibroblast cell therapy platform.
FibroGenesis Inks Manufacturing Agreement contractpharma
September 30, 2020
Engages CDMO iBiologics to manufacture proprietary fibroblasts.
FibroGenesis Files Expanded Patent Coverage for Fibroblast Cell Therapy for COVID-19 ARDS americanpharmaceuticalreview
April 02, 2020
FibroGenesis announced the filing of United States Provisional Patent Number 63/002,134 titled, "Peptides and Adjuvants for Augmentation of Fibroblast Therapy for Coronavirus."